The PB NK function was then assessed by redirected antibody-dependent cell-mediated cytotoxicity (rADCC), by specifically triggering NKG2D with an anti-NKG2D mAb in the presence of P815 target cells bearing Ig Fc receptors, with or without prior stimulation with IL-15, an emerging tool to harness NK cell-mediated anti-cancer immunotherapy [27,28]. The gene discussed is IL15; the disease is cancer.